This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -13.64% and 26.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $5.84, denoting a +1.83% change from the preceding trading day.
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.
Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) reachead $5.41 at the closing of the latest trading day, reflecting a -1.64% change compared to its last close.
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
by Zacks Equity Research
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today
by Zacks Equity Research
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $6.48, denoting a -1.52% change from the preceding trading day.
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
Company News for Mar 3, 2025
by Zacks Equity Research
Companies In The News Are: AES, RXRX, PAR, MOS.
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -47.22% and 84.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -29.73% and 7.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
by Ahan Chakraborty
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $7.25, representing a +0.14% change from its previous close.
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day.
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -3.03% and 24.86%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close.
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.68, signifying a -0.89% move from its prior day's close.
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close.
Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know
by Zacks Equity Research
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.67, marking a -0.74% move from the previous day.